Financial Press Releases

Interim results for the six months ended 30 June 2020
Interim results for the six months ended 30 June 2020
August 10, 2020

Proteome Sciences announces its unaudited interim results for the six months ended 30 June 2020.

Holding(s) in Company
Holding(s) in Company
July 27, 2020

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 24 July 2020.

Director/PDMR Shareholding
Director/PDMR Shareholding
July 7, 2020

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 3 July 2020 it purchased 99,999 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 3.90p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,463,157 Ordinary Shares, equivalent to 22.18% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
July 2, 2020

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 30 June and 1 July 2020 it purchased 100,000 and 60,000 Ordinary Shares of 1p, respectively,  in the capital of the Company ("Ordinary Shares") at an average price of 3.95p per Ordinary Share (the “Purchase”). Following the Purchase, Vulpes has a total direct and indirect interest in 65,363,158 Ordinary Shares, equivalent to 22.14% of Proteome Sciences' total issued share capital.

Shareholder Questions & Answers - AGM 26 June 2020
Shareholder Questions & Answers - AGM 26 June 2020
June 26, 2020

Shareholder Questions & Answers 26 June 2020.

The following questions were submitted by Shareholders prior to the Company’s AGM held at 11 am on 26 June in a closed session due to COVID-19 restrictions. They have been put into appropriate categories and similar questions amalgamated.

The Company has prepared a new presentation for shareholders
The Company has prepared a new presentation for shareholders
June 26, 2020

The Company has prepared a new presentation for shareholders.

 

Result of Annual General Meeting (AGM)
Result of Annual General Meeting (AGM)
June 26, 2020

The directors of Proteome Sciences are pleased to announce that at the Company's AGM, held at 11.00 a.m. today, all resolutions were duly passed.

The Company has prepared a new presentation for shareholders and a copy will be available on the Company’s website later today.

Annual General Meeting (AGM) Statement
Annual General Meeting (AGM) Statement
June 26, 2020

At the Company’s AGM being held today at 11.00 am, the Chairman, Christopher Pearce, will make the following statement.

 “Following the delivery of a profit after tax in 2019, we are pleased to report continued progress throughout the business. We have experienced good growth in services revenues and sales of both TMT® and TMTpro™ have remained stable over the first 5 months of the year. Despite the challenges of the COVID-19 pandemic, our dedicated staff have ensured we remained fully operational and have delivered 11 projects carried over from 2019 for which we already had samples. A further 10 projects are ongoing and new orders are also being generated. We expect these trends to continue through the rest of the year”

Notice of Annual General Meeting
Notice of Annual General Meeting
June 2, 2020

Proteome Sciences Plc (AIM: PRM), the specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, announces that the Company's 2020 Annual General Meeting (the "AGM") will be held at 11.00 am on 26 June 2020 at Nicholson House, Thames Street, Weybridge KT13 8JG. Notification of the AGM and proxy form have been posted to shareholders and will shortly be available on the Company's website. 

Notice of Annual General Meeting 

Letter from the Chairman

Proxy Form

Holding(s) in Company
Holding(s) in Company
April 30, 2020

Holding(s) in Company - TR-1 notification was received from Helium Special Situations Fund on the 30 April 2020.